Oxytocin Research Peptide Hub

Oxytocin is a cyclic nonapeptide which occurs naturally and is a member of the neurohypophyseal peptide family; its primary structure is made up of nine amino acids with a disulfide bond joining the cysteine residues found at positions 1 and 6. This covalent bond results in a six-amino acid cyclic section together with a short C-terminal tripeptide sequence. The glycine at the C-terminus is amidated.

Oxytocin is known in the fields of biochemical and molecular research since its compact cyclic structure serves as a well-defined model for the study of peptide conformation, disulfide-bond formation, receptor–ligand recognition, and G-protein-coupled receptor signaling.

Oxytocin can be studied in laboratory conditions through the use of peptide chemistry, receptor-binding techniques, methods from structural biology, as well as chromatographic and mass-spectrometric methods. The research material can be analysed with well-established analytical techniques to determine its identity, purity, molecular mass and properties related to its sequence.

The glycine at the C-terminus is amidated, which is an important structural characteristic of the mature peptide; oxytocin thus contains peptide bonds, side chains with amide groups, a phenolic tyrosine residue and a covalent disulfide bond all within a fairly compact molecular structure.

The way in which it adopts different conformations is affected by the region containing the cyclic disulfide and by the interactions between the polar and hydrophobic side chains of the amino acids. Investigations into the structure have looked at the role this conformation plays in molecular recognition by the oxytocin receptor. High-resolution studies of the receptor have given direct information about the position of the cyclic peptide in the receptor-binding pocket.

For other peptides which have disulfide bonds, laboratory stability can be affected by temperature, the oxidation state, moisture, pH and frequent handling as well; furthermore, solubility and solution stability will also depend on concentration, solvent composition and the experimental conditions.

The main way oxytocin is described in published experimental research is through its interaction with the class A G protein-coupled receptor, the oxytocin receptor (OTR). Oxytocin and the orthosteric ligand-binding pocket of the receptor have been shown to interact through structural studies, which have also identified certain molecular interactions involved in ligand recognition. An oxytocin-bound OTR signaling complex has been resolved at around 3.2 Å resolution using cryo-electron microscopy, offering molecular-level details regarding ligand placement and receptor activation.

Further research has looked at the downstream pathways linked to OTR activation, such as mitogen-activated protein kinase signaling, Rho-associated pathways and receptor regulatory processes. Investigations have also been carried out into GPCR kinase-mediated receptor phosphorylation, β-arrestin recruitment, receptor desensitization and internalization as part of the regulation of OTR signaling.

Structural and pharmacological studies additionally investigate the relationship between oxytocin and closely related vasopressin-family receptors. Because these receptors belong to a structurally related GPCR subfamily, receptor-selectivity experiments and ligand-binding studies are used to characterize the molecular determinants responsible for oxytocin recognition.

The studies offer a laboratory setting in which peptide–receptor interactions, changes in GPCR conformation, second-messenger signalling and ligand specificity can be examined without having to rely on therapeutic or outcome-based interpretations.

Synthetic oxytocin can be produced by means of well-established peptide-synthesis methods, such as solid-phase peptide synthesis (SPPS), after which the molecule is cleaved, the protective groups are removed and the disulfide bond between Cys¹ and Cys⁶ is formed under controlled conditions. It is usual for the subsequent purification to involve preparative reversed-phase high-performance liquid chromatography.

Peptide-related contaminants can be detected and the chromatographic purity can be determined by means of analytical HPLC. Liquid chromatography–mass spectrometry (LC-MS) provides additional confirmation of identity by calculating the molecular mass and looking at the mass-to-charge signals which correspond to the target peptide.

Where necessary, further analytical methods can be used to examine sequence integrity, disulfide bond formation or peptide-related degradation products.

In order to comply with Broad Payments requirements, an independent Certificate of Analysis specific to the batch in question should identify the compound, the batch or lot number, the date of the testing, the analytical method used and the measured purity. The compliance document sets out a minimum purity standard of 98% and says that the relevant COA should be shown on the individual product page.

Lyophilised peptides must be stored at controlled low temperatures, protected from moisture and direct light, unless the batch-specific documentation states otherwise. When it comes to long-term storage in the laboratory, storage at around −20°C in a dry and sealed environment is appropriate, on the condition that the product documentation is available.

When it is necessary to prepare a laboratory solution, the suitable research solvent should be chosen on the basis of the experimental method. The prepared solutions should be handled in accordance with the appropriate laboratory procedures and, wherever possible, repeated freeze/thaw cycles should be avoided. Solution stability should be evaluated taking into account concentration, solvent, pH and the conditions under which the solutions are stored.